Annexin Pharmaceuticals AB (publ) Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 39.6M 3.64M 291M | Capitalization | 104M 9.55M 763M |
---|---|---|---|---|---|
Net income 2024 * | -52M -4.78M -382M | Net income 2025 * | -16M -1.47M -117M | EV / Sales 2024 * | - |
Net cash position 2024 * | 18.4M 1.69M 135M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.63 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.9% |
Managers | Title | Age | Since |
---|---|---|---|
Anna Frostegård
FOU | Founder | 51 | 31/12/13 |
Chief Executive Officer | 63 | 31/12/17 | |
Director of Finance/CFO | 53 | 10/04/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 31/12/20 |
Mårten Österlund
BRD | Director/Board Member | 67 | 31/12/20 |
Chief Executive Officer | 63 | 31/12/17 |
1st Jan change | Capi. | |
---|---|---|
-1.10% | 104B | |
+6.95% | 97.47B | |
+5.71% | 22.25B | |
-13.03% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.50% | 16.36B | |
+8.23% | 14.39B | |
+39.57% | 12.37B |